Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BMPR1B | O00238 | 6/20 | 0.41 |
| ▸ | BMPR1A | P36894 | 6/20 | 0.41 |
| ▸ | TGFBR1 | P36897 | 6/20 | 0.41 |
| ▸ | ACVRL1 | P37023 | 6/20 | 0.41 |
| ▸ | ACVR1 | Q04771 | 6/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | HTR3A | P46098 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3471910 | 0.84 | BMPR1B (0.41) | BMPR1BBMPR1ATGFBR1ACVRL1ACVR1 | |
| SCHEMBL3469782 | 0.84 | SLC6A2 (0.48) | HTR3A | |
| SCHEMBL4192237 | 0.81 | SLC6A4 (0.50) | BMPR1BBMPR1ATGFBR1ACVRL1ACVR1 | |
| SCHEMBL15641092 | 0.81 | SLC6A4 (0.50) | BMPR1BBMPR1ATGFBR1ACVRL1ACVR1 | |
| SCHEMBL31285608 | 0.81 | SLC6A4 (0.50) | BMPR1BBMPR1ATGFBR1ACVRL1ACVR1 | |
| SCHEMBL4183125 | 0.81 | SLC6A4 (0.50) | BMPR1BBMPR1ATGFBR1ACVRL1ACVR1 | |
| SCHEMBL4188380 | 0.81 | SLC6A4 (0.50) | BMPR1BBMPR1ATGFBR1ACVRL1ACVR1 | |
| SCHEMBL20459048 | 0.81 | SLC6A4 (0.50) | BMPR1BBMPR1ATGFBR1ACVRL1ACVR1 | |
| SCHEMBL15641093 | 0.81 | SLC6A4 (0.50) | BMPR1BBMPR1ATGFBR1ACVRL1ACVR1 | |
| SCHEMBL3469837 | 0.81 | KCNH2 (0.39) | CYP1A2HTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140303207-A1 | Novel 1-Heteroaryl-3-Azabicyclo[3.1.0]Hexanes Methods For Their Preparation And Their Use As Medicaments | NEUROVANCE, INC. (US) | 2014-10-09 | — | — | US | claimed |
| EP-2167083-A2 | NOVEL 1- HETEROARYL-3-AZABICYCLOÝ3.1.0¨HEXANES, METHODS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | DOV Pharmaceutical, Inc. (US) | 2010-03-31 | — | — | EP | claimed |
| WO-2008153937-A2 | NOVEL 1- HETEROARYL-3-AZABICYCLO[3.1.0]HEXANES, METHODS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | DOV PHARMACEUTICAL, INC. (US) | 2008-12-18 | — | — | WO | claimed |
| US-20240409514-A1 | METHODS FOR INHIBITING NATIVE AND PROMISCUOUS UPTAKE OF MONOAMINE NEUROTRANSMITTERS | ETHISMOS RESEARCH, INC. (US) | 2024-12-12 | — | — | US | disclosed |
| US-20210047268-A1 | METHODS FOR INHIBITING NATIVE AND PROMISCUOUS UPTAKE OF MONOAMINE NEUROTRANSMISTTERS | ETHISMOS RESEARCH, INC. | 2021-02-18 | — | — | US | disclosed |
| US-20210023049-A1 | Novel 1-Aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | DOV PHARMACEUTICAL, INC. | 2021-01-28 | — | — | US | disclosed |
| US-20190070148-A1 | Novel 1-Aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | DOV PHARMACEUTICAL, INC. | 2019-03-07 | — | — | US | disclosed |
| EP-2719384-B1 | Novel 1-naphthyl-3-azabicyclo[3.1.0]hexanes:preparation and use to treat neuropsychiatric disorders | OTSUKA AMERICA PHARMACEUTICAL INC (US) | 2018-08-08 | — | — | EP | disclosed |
| US-10039746-B2 | 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders | OTSUKA AMERICA PHARMACEUTICAL, INC. (US) | 2018-08-07 | — | — | US | disclosed |
| US-20180215710-A1 | METHODS FOR INHIBITING NATIVE AND PROMISCUOUS UPTAKE OF MONOAMINE NEUROTRANSMITTERS | EUTHYMICS BIOSCIENCE, INC. | 2018-08-02 | — | — | US | disclosed |
| US-20180000777-A1 | Novel 1-Aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | EUTHYMICS BIOSCIENCE, INC. | 2018-01-04 | — | — | US | disclosed |
| US-20090069374-A1 | Novel 1-Heteroaryl-3-Azabicyclo[3.1.0]Hexanes, Methods For Their Preparation And Their Use As Medicaments | ETHISMOS RESEARCH, INC. | 2009-03-12 | — | — | US | disclosed |
| US-20090069374-A1 | Novel 1-Heteroaryl-3-Azabicyclo[3.1.0]Hexanes, Methods For Their Preparation And Their Use As Medicaments | ETHISMOS RESEARCH, INC. | 2009-03-12 | — | — | US | disclosed |
| US-20090069374-A1 | Novel 1-Heteroaryl-3-Azabicyclo[3.1.0]Hexanes, Methods For Their Preparation And Their Use As Medicaments | ETHISMOS RESEARCH, INC. | 2009-03-12 | — | — | US | disclosed |
| WO-2008153937-A2 | NOVEL 1- HETEROARYL-3-AZABICYCLO[3.1.0]HEXANES, METHODS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | DOV PHARMACEUTICAL, INC. (US) | 2008-12-18 | — | — | WO | disclosed |
| WO-2008153937-A2 | NOVEL 1- HETEROARYL-3-AZABICYCLO[3.1.0]HEXANES, METHODS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | DOV PHARMACEUTICAL, INC. (US) | 2008-12-18 | — | — | WO | disclosed |
| EP-1915146-A2 | NOVEL 1-ARYL-3-AZABICYCLOÝ3.1.0¨HEXANES: PREPARATION AND USE TO TREAT NEUROPSYCHIATRIC DISORDERS | DOV Pharmaceutical, Inc. (US) | 2008-04-30 | — | — | EP | disclosed |
| US-20070082940-A1 | Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders | OTSUKA AMERICA PHARMACEUTICAL, INC. | 2007-04-12 | — | — | US | disclosed |
| WO-2007016155-A2 | NOVEL 1-ARYL-3-AZABICYCLO[3.1.0]HEXANES: PREPARATION AND USE TO TREAT NEUROPSYCHIATRIC DISORDERS | DOV PHARMACEUTICAL, INC. (US) | 2007-02-08 | — | — | WO | disclosed |
| US-20060223875-A1 | Methods and compositions for production, formulation and use of 1-aryl-3-azabicyclo[3.1.0]hexanes | DOV PHARMACEUTICAL, INC. | 2006-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210047268-A1 | METHODS FOR INHIBITING NATIVE AND PROMISCUOUS UPTAKE OF MONOAMINE NEUROTRANSMISTTERS | SLC18A2, SLC6A2, SLC6A3 | BMPR1B 2677/4885BMPR1A 2499/4885TGFBR1 3607/4885 |
| US-20140303207-A1 | Novel 1-Heteroaryl-3-Azabicyclo[3.1.0]Hexanes Methods For Their Preparation And Their Use As Medicaments | HTR3C, HTR2C, CNR1 | BMPR1B 1117/4885BMPR1A 1188/4885TGFBR1 3108/4885 |
| US-10039746-B2 | 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders | HTR3C, HTR1D, HTR1B | BMPR1B 524/4885BMPR1A 715/4885TGFBR1 2569/4885 |
| US-20180215710-A1 | METHODS FOR INHIBITING NATIVE AND PROMISCUOUS UPTAKE OF MONOAMINE NEUROTRANSMITTERS | SLC18A2, SLC6A2, SLC18A3 | BMPR1B 1817/4885BMPR1A 1881/4885TGFBR1 2755/4885 |
| US-20070082940-A1 | Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders | HTR3C, HTR1B, HTR2C | BMPR1B 451/4885BMPR1A 665/4885TGFBR1 2734/4885 |
| US-20180000777-A1 | Novel 1-Aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | HTR3C, HTR1B, HTR2C | BMPR1B 451/4885BMPR1A 665/4885TGFBR1 2734/4885 |
| US-20090069374-A1 | Novel 1-Heteroaryl-3-Azabicyclo[3.1.0]Hexanes, Methods For Their Preparation And Their Use As Medicaments | HTR3C, HTR2C, GRIN2C | BMPR1B 1160/4885BMPR1A 1059/4885TGFBR1 3326/4885 |
| US-20240409514-A1 | METHODS FOR INHIBITING NATIVE AND PROMISCUOUS UPTAKE OF MONOAMINE NEUROTRANSMITTERS | SLC18A2, SLC6A2, SLC18A3 | BMPR1B 1817/4885BMPR1A 1881/4885TGFBR1 2755/4885 |
| US-20190070148-A1 | Novel 1-Aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | HTR3C, HTR1B, HTR2C | BMPR1B 451/4885BMPR1A 665/4885TGFBR1 2734/4885 |
| US-20210023049-A1 | Novel 1-Aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | HTR3C, HTR1B, HTR2C | BMPR1B 451/4885BMPR1A 665/4885TGFBR1 2734/4885 |
| US-20060223875-A1 | Methods and compositions for production, formulation and use of 1-aryl-3-azabicyclo[3.1.0]hexanes | HTR1B, SLC6A3, CYP1B1 | BMPR1B 361/4885BMPR1A 605/4885TGFBR1 2500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.